RND2 and melanoma: We were interested in reactivation of TGFBI (transforming growth factor, beta-induced, 68 kDa), because it is one of the novel genes that was not previously reported to be controlled by DNA methylation and it belongs to a set of ∼11 genes active in normal human melanocytes, silenced in melanoma cells, and reactivated by low-dose Aza (COL1A2, CTSK, GLB1L, IL11RA, MMP1, RND2, SERINC2, STC1, TNFRSF10D, FLJ22662) (Figures 2B and 7A), and thus has the potential to serve as a marker for melanoma progression and responsiveness to Aza.